Medical significance and new therapeutical strategies for biofilm associated infections
- PMID: 21434589
Medical significance and new therapeutical strategies for biofilm associated infections
Abstract
Recent public announcements stated that 60% to 85% of all microbial infections involve biofilms developed on natural tissues (skin, mucosa, endothelial epithelia, teeth, bones) or artificial devices (central venous, peritoneal and urinary catheters, dental materials, cardiac valves, intrauterine contraceptive devices, contact lenses, different types of implants). Prosthetic medical devices are risk factors of chronic infections in developed countries and these infections are characterized by slow onset, middle intensity symptoms, chronic evolution and resistance to antibiotic treatment. In case of biofilm development, a series of genes (40-60% of the prokaryotic genome) are modulated (activated/inhibited) by complex cell to cell signalling mechanisms and the biofilm cells become phenotypically distinct from their counterpart--free cells, being more resistant to stress conditions (including all types of antimicrobial substances); this resistance is phenotypical, behavioural and, more recently, called TOLERANCE. Four major mechanisms can account for biofilm antibiotic tolerance: (1) the failure of antibiotic penetration into the depth of a mature biofilm due to the biofilm matrix; (2) the accumulation of high levels of antibiotic degrading enzymes; (3) in the depth of biofilm, cells are experiencing nutrient limitation entering in a slow-growing or starved state; slow-growing or non-growing cells being not highly susceptible to antimicrobial agents, this phenomenon could be amplified by the presence of phenotypic variants or "persisters" and (4) biofilm's bacteria can turn on stress-response genes and switch to more tolerant phenotypes on exposure to environmental stresses; (5) genetic changes, probably selected by different stress conditions, such as mutations and gene transfer could occur inside the biofilm. In these conditions, biofilm associated infections require a different approach, both clinically and paraclinically.
Similar articles
-
Quorum sensing in biofilms--how to destroy the bacterial citadels or their cohesion/power?Anaerobe. 2011 Dec;17(6):280-5. doi: 10.1016/j.anaerobe.2011.03.023. Epub 2011 Apr 8. Anaerobe. 2011. PMID: 21497662 Review.
-
Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems?Adv Drug Deliv Rev. 2005 Jul 29;57(10):1539-50. doi: 10.1016/j.addr.2005.04.007. Adv Drug Deliv Rev. 2005. PMID: 15950314 Review.
-
The physiology and collective recalcitrance of microbial biofilm communities.Adv Microb Physiol. 2002;46:202-56. Adv Microb Physiol. 2002. PMID: 12073654 Review.
-
Biofilms in ear, nose, and throat infections: how important are they?Laryngoscope. 2007 Apr;117(4):668-73. doi: 10.1097/MLG.0b013e318030e422. Laryngoscope. 2007. PMID: 17415138 Review.
-
New antibiotic agents and approaches to treat biofilm-associated infections.Expert Opin Ther Pat. 2010 Oct;20(10):1373-87. doi: 10.1517/13543776.2010.505923. Expert Opin Ther Pat. 2010. PMID: 20636186 Review.
Cited by
-
Bioactive Surfaces of Polylactide and Silver Nanoparticles for the Prevention of Microbial Contamination.Materials (Basel). 2020 Feb 7;13(3):768. doi: 10.3390/ma13030768. Materials (Basel). 2020. PMID: 32046134 Free PMC article.
-
Bioevaluation of novel anti-biofilm coatings based on PVP/Fe3O4 nanostructures and 2-((4-ethylphenoxy)methyl)-N- (arylcarbamothioyl)benzamides.Molecules. 2014 Aug 12;19(8):12011-30. doi: 10.3390/molecules190812011. Molecules. 2014. PMID: 25120054 Free PMC article.
-
Resistance, Tolerance, Virulence and Bacterial Pathogen Fitness-Current State and Envisioned Solutions for the Near Future.Pathogens. 2023 May 22;12(5):746. doi: 10.3390/pathogens12050746. Pathogens. 2023. PMID: 37242416 Free PMC article. Review.
-
Aspects of Gut Microbiota and Immune System Interactions in Infectious Diseases, Immunopathology, and Cancer.Front Immunol. 2018 Aug 15;9:1830. doi: 10.3389/fimmu.2018.01830. eCollection 2018. Front Immunol. 2018. PMID: 30158926 Free PMC article. Review.
-
Functionalized Self-Assembled Monolayers: Versatile Strategies to Combat Bacterial Biofilm Formation.Pharmaceutics. 2022 Aug 2;14(8):1613. doi: 10.3390/pharmaceutics14081613. Pharmaceutics. 2022. PMID: 36015238 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical